Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 1517 results for patients and public

  1. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development Reference number: GID-TA11221 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487]

    In development Reference number: GID-TA11628 Expected publication date:  11 March 2026

    Technology appraisal guidance
    In development

  3. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]

    In development Reference number: GID-TA11414 Expected publication date:  10 June 2026

    Technology appraisal guidance
    In development

  4. Overweight and obesity management (NG246)

    This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on overweight and obesity. It does not cover pregnancy.

    NICE guideline
    Last updated
    8 January 2026

    Sections for NG246

  5. Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation

    In development Reference number: GID-IPG10416 Expected publication date:  25 February 2026

    Interventional procedures guidance
    In development

  6. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development Reference number: GID-TA11220 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]

    In development Reference number: GID-TA11554 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Atogepant for treating migraine [ID6615]

    In development Reference number: GID-TA11817 Expected publication date:  09 July 2026

    Technology appraisal guidance
    In development

  9. Flu vaccination: increasing uptake (NG103)

    This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.

    NICE guideline
    Published
    22 August 2018
    View recommendations

    Sections for NG103

  10. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31) [ID6598]

    In development Reference number: GID-HST10067 Expected publication date:  19 August 2026

    Highly specialised technologies guidance
    In development

  11. Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]

    In development Reference number: GID-TA11502 Expected publication date:  02 December 2026

    Technology appraisal guidance
    In development

  12. Leadless cardiac pacemaker implantation for bradyarrhythmias

    In development Reference number: GID-IPG10340 Expected publication date:  25 February 2026

    Interventional procedures guidance
    In development

  13. Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]

    In development Reference number: GID-TA11477 Expected publication date:  12 August 2026

    Technology appraisal guidance
    In development

  14. Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]

    In development Reference number: GID-TA11768 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  15. Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

    Awaiting development Reference number: GID-TA11565 Expected publication date:  21 May 2026

    Technology appraisal guidance
    Awaiting development